Crossmark

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy

Crossref DOI link: https://doi.org/10.1038/s41541-022-00433-9

Published Online: 2022-02-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Salvatori, Erika https://orcid.org/0000-0001-9875-4465
Lione, Lucia https://orcid.org/0000-0001-8927-1832
Compagnone, Mirco https://orcid.org/0000-0002-0199-8007
Pinto, Eleonora https://orcid.org/0000-0003-4955-5528
Conforti, Antonella https://orcid.org/0000-0001-8524-5936
Ciliberto, Gennaro

Aurisicchio, Luigi https://orcid.org/0000-0003-3110-4534
Palombo, Fabio https://orcid.org/0000-0003-0473-4901
License Information

Text and Data Mining valid from 2022-02-02

Version of Record valid from 2022-02-02
More Information

Article History

Received: 15 August 2021

Accepted: 16 December 2021

First Online: 2 February 2022

Competing interests

: The authors declare no competing interests.